Thursday, January 21, 2016 12:51:41 PM
The company released the following statement: "The company has received a detailed response to the Pre-IND submission sent to the U.S. Food and Drug Administration for the further development of the patented migraine medicine the company has ownership in. The FDA has responded in supplying the company with a clear roadmap to develop a 4 arm study wherein the medicine will be dispensed in an emergency room setting for patients that enter the ER for migraine relief. This study will give the company feedback on the efficacy of the drug as compared to other medications currently being dispensed to relieve migraines. This study significantly will speed up the process to bring the product to market."
The company also stated it is suspending all other areas of business to focus 100% on the further development of the medicine. As the migraine industry in the U.S. is currently in excess of $800 Million per year, the company feels that this medicine could capture a 10-15% market share which would place a value of the medicine at $80-$120 Million.
Just another board
http://investorshub.advfn.com/boards/board.asp?board_id=9248
My posts are just my opinions
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM